KI
VRAX icon

Kapitalo Investimentos’s Virax Biolabs VRAX Stock Holding History

Kapitalo Investimentos’s Portfolio VRAX Stock Details VRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-470
Closed -$858K – 509
2022
Q4 		$858K Buy
+470
New +$167K 0.64% 21

Other funds holding VRAX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Kapitalo Investimentos's VRAX Position: Q1 2023 in Review

Kapitalo Investimentos sold out of Virax Biolabs (VRAX) in Q1 2023, closing a stake of 470 shares — an estimated $858K sold.

Kapitalo Investimentos first reported a position in VRAX in Q4 2022 and held it in 1 quarter. The position peaked at $858K in Q4 2022. 5 funds tracked by Wall St. Rank hold VRAX as of Q1 2023.

  • Kapitalo Investimentos reported no remaining Virax Biolabs position as of Q1 2023 after selling out during the quarter.
  • Kapitalo Investimentos sold 470 Virax Biolabs shares in Q1 2023, an estimated $858K.
  • Kapitalo Investimentos first reported a position in Virax Biolabs in Q4 2022 and held it in 1 quarter.
  • Kapitalo Investimentos's Virax Biolabs position peaked at $858K in Q4 2022.
  • 5 funds tracked by Wall St. Rank held Virax Biolabs as of Q1 2023.

Based on Kapitalo Investimentos's 13F filing for Q1 2023, filed 29 Mar 2024.